• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Ainos Inc.

    8/21/24 8:22:28 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email
    SC 13D 1 formsc13d.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

     

    Ainos, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    00902F303

    (CUSIP Number)

     

    Chun-Hsien Tsai

    Chief Executive Officer

    Ainos, Inc.

    14F., No. 61, Sec. 4, New Taipei Boulevard, Xinzhuang District

    New Taipei City 242, Taiwan F5

    886-37-581999

    (Name, Address and Telephone Number of Person Authorized to
    Receive Notices and Communications)

     

    August 15, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 00902F303

     

    1

    NAME OF REPORTING PERSON:

     

    Taiwan Carbon Nano Technology Corporation (“TNCT”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ☒

    (b) ☐

    3

    SEC USE ONLY:

     

    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

     

    OO

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Taiwan, Republic of China

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7

    SOLE VOTING POWER:

     

    0

    8

    SHARED VOTING POWER:

     

    5,500,000 (1)

    9

    SOLE DISPOSITIVE POWER:

     

    5,500,000 (1)

    10

    SHARED DISPOSITIVE POWER:

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    5,500,000 (1)

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

     

    40.23% (2)

    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    CO

     

     

    (1)Represents beneficial ownership of 5,500,000 shares of common stock, $0.01 par value (the “Common Stock”), of Ainos, Inc., a Texas corporation (the “Issuer”), which are subject to a voting agreement between TCNT and Ainos Inc., a Cayman Islands corporation (“Ainos KY”). For further details, please see Item 3 and Item 6.
    (2)Based on the sum of (i) 7,663,022 shares of Common Stock outstanding as of August 2, 2024 as set forth in the Quarterly Report on Form 10-Q of the Issuer filed with the SEC on August 5, 2024, (ii) 382,384 shares of Common Stock issued to an institutional investor upon conversion of certain convertible notes on August 5, 2024, (iii) 5,500,000 shares of Common Stock issued to TCNT pursuant to the patent license agreement (the “License Agreement”) by and between the Issuer and TCNT, dated August 15, 2024, and (iv) 126,060 restricted stock units that vested on August 15, 2024 under the Ainos, Inc. 2023 Stock Incentive Plan.

     

     
     

     

    Item 1. Security and Issuer

     

    This Schedule 13D is being filed to reflect the acquisition by Taiwan Carbon Nano Technology Corporation (“TCNT”) of 5,500,000 shares of Common Stock pursuant to a patent license agreement, dated August 6, 2024, by and between the Issuer and TCNT.

     

    This statement on Schedule 13D (this “Statement”) relates to the Common Stock, par value $0.01 per share of the Issuer. The address of the principal executive corporate offices of the Issuer is 10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 302 , Taiwan (R.O.C.).

     

    Item 2. Identity and Background

     

    (a)-(c) This Schedule 13D is being filed by Taiwan Carbon Nano Technology Corporation, a Taiwanese corporation, with a principal executive office at 10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 302 , Taiwan (R.O.C.).

     

    The principal business of TCNT includes the development of advanced materials for industrial and medical device applications.

     

    For disclosure relating to the directors and executive officers of TCNT, see Schedule A hereto.

     

    (d) During the last five years, none of the reporting person nor any director or executive officer of the reporting person have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) During the last five years, none of the reporting person nor any director or executive officer of reporting person was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) The reporting person is organized in Taiwan, Republic of China.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    On August 6, 2024, the Issuer entered into the License Agreement with TCNT. Pursuant to the License Agreement, TCNT has agreed to assign and grant, and the Company has agreed to accept, an exclusive, irrevocable, and perpetual license of certain invention patents and patent applications related to gas sensors and medical devices (the “Licensed Patents”), in exchange for 5,500,000 shares of the Common Stock, at a price per share of 1.05 times the highest closing sale price of the Common Stock during the 30-trading day period preceding the effective date of the License Agreement. On August 15, 2024, the Issuer issued the 5,500,000 shares to TCNT pursuant to the License Agreement.

     

    Item 4. Purpose of Transaction

     

    The shares were issued to TCNT as the consideration pursuant to the License Agreement the Issuer entered into and consummated on August 6, 2024.

     

    Except to the extent provided in this Statement, the reporting person has no current plans or proposals that relate to or could result in any of the matters referred to in paragraphs (a) through (j) inclusive, of Item 4 of Schedule 13D. The reporting person may, at any time and from time to time, review or reconsider their positions and/or change their purposes and/or formulate plans or proposals with respect thereto.

     

     
     

     

    Item 5. Interest in Securities of the Issuer

     

    (a) - (b) The information requested by these paragraphs are incorporated herein by reference to the cover pages to this Statement.

     

    (c) The reporting person has not effected any transactions in Common Stock during the past 60 days, except as described in this Statement.

     

    (d) The information in Item 2 is incorporated by reference into this Item 5(d).

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    The reporting person’s responses to Items 3 – 5 are incorporated by reference into this Item 6.

     

    TCNT directly holds 5,500,000 shares of Common Stock.

     

    Effective August 15, 2024, Ainos Inc., a Cayman Islands company (“Ainos KY”) and TCNT entered into a voting agreement (the “Voting Agreement”) with respect to the voting stock of the Issuer held by TCNT. Pursuant to the Voting Agreement, TCNT has agreed to vote all of the voting stock of the Company that is current owns or will acquire in the future in the manner determined by Ainos KY in its sole discretion. The Voting Agreement may only be terminated if (i) Ainos KY directly holds less than 10% of the shares of the Issuer; or (ii) when Ainos KY directly holds shares which have less than 10% of the voting power in the Issuer. This voting agreement will cease to apply to a particular stockholder when the stockholder holds no shares in the Issuer; or when the stockholder ceases to be subject to the obligations under Section 16 of the Securities Exchange Act of 1934, as amended, if applicable.

     

    Except as set forth herein, the reporting person has no other contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

     

    Item 7. Material to be Filed as Exhibit

     

    Exhibit No.   Description
    1   Voting Agreement, dated August 15, 2024, between Ainos, Inc. and Taiwan Carbon Nano Technology Corporation (incorporated by reference to Exhibit 1 of the Amendment No. 8 to the Schedule 13D filed with the SEC on August 20, 2024)

     

     
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 21, 2024

     

      Taiwan Carbon Nano Technology Corporation
         
      By: /s/ Tsai, Chun-Hsien
      Name: Tsai, Chun-Hsien
      Title: Chairman, Chief Executive Officer

     

     
     

     

    Schedule A

     

    Directors and Executive Officers of Taiwan Carbon Nano Technology Corporation

     

    Name   Principal Occupation (and name/address of employer if not one of the entities listed on this Schedule)   Principal Business Address   Interest in Issuer (in shared of Common Stock)
    Ting-Chuan Lee   Director of TCNT and employee director of the Issuer   See Note 1.   95,2312
    Chung Yi-Tsai   Director of TCNT and non-employee director of the Issuer   See Note 1.   52,9324
    Chun-Hsien Tsai   Director of Ainos KY, Chairman and Chief Executive Officer of TCNT, and Chairman, President, and CEO of the Issuer   See Note 1.   302,3192
    Chun-Jung Tsai   Director of each of Ainos KY and TCNT and employee director of the Issuer   See Note 1.   88,3863
    Ching-Ho Tsai   Director of TCNT   See Note 1.   None
    A-Wen Tsai Huang   Supervisor of TCNT   See Note 1.   None

     

    Note 1: The address of each individual is c/o 10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 30261, Taiwan (R.O.C.) and each individual is a citizen of Taiwan.

     

    Note 2: The combined beneficial ownership of Chun-Hsien Tsai and Ting Chuan Lee totals 397,550 shares. Chun-Hsien Tsai directly and beneficially owns 302,319 shares, and his wife, Ting Chuang Lee directly and beneficially owns 95,231 shares.

     

    Note 3: Chun-Jung Tsai beneficially owns 88,386 shares of Common Stock of the Issuer.

     

    Note 4: Chung Yi-Tsai beneficially owns 52,932 shares of Common Stock of the Issuer.

     

     

    Get the next $AIMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIMD
    Financials

    Live finance-specific insights

    See more
    • Ainos Reports Third Quarter 2024 Financial Results

      Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts. SAN DIEGO, CA / ACCESSWIRE / November 6, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its financial results for the third quarter ended September 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, Preside

      11/6/24 4:30:00 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Reports Second Quarter 2024 Financial Results

      Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12 months following the prepayment of a senior secured convertible noteSAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA®"), today announced its financial results for the second quarter ended June 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We've made meaningful progress

      8/5/24 4:15:00 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Reports First Quarter 2024 Financial Results

      Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "In the first quarter, we successfully

      5/13/24 4:10:00 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    SEC Filings

    See more
    • SEC Form PRE 14C filed by Ainos Inc.

      PRE 14C - Ainos, Inc. (0001014763) (Filer)

      5/19/25 4:15:23 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ainos Inc.

      10-Q - Ainos, Inc. (0001014763) (Filer)

      5/14/25 4:05:51 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ainos, Inc. (0001014763) (Filer)

      5/12/25 9:01:07 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025

      Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health.Key Highlights from the Report:AI Nose Technolog

      1/21/25 10:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

      SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule").As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below

      1/17/25 9:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

      Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

      1/13/25 10:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AIMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AIMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13D/A filed by Ainos Inc.

      SC 13D/A - Ainos, Inc. (0001014763) (Subject)

      11/27/24 6:08:44 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Ainos Inc.

      SC 13D - Ainos, Inc. (0001014763) (Subject)

      8/21/24 8:22:28 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ainos Inc.

      SC 13D/A - Ainos, Inc. (0001014763) (Subject)

      8/20/24 4:05:21 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tsai Chun-Jung was granted 900,000 shares, increasing direct ownership by 170% to 1,427,900 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:35 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Ting-Chuan was granted 900,000 shares, increasing direct ownership by 169% to 1,431,432 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:38 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO, PRESIDENT, CHAIRMAN Tsai Chun-Hsien was granted 900,000 shares, increasing direct ownership by 120% to 1,651,862 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:36 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

      Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

      1/13/25 10:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care